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STRAIN SPECIFICITY OF CAPSULAR POLYSACCHARIDE PRODUCTION 
BY STAPHYLOCOCCUS AUREUS 
ANTHONY J. YEH 
ABSTRACT 
Staphylococcus aureus is the leading cause of nosocomial infections in the US and 
is becoming increasingly difficult to treat due to the limited antibiotics available. Capsular 
polysaccharides (CP), a virulence factor produced by the bacterium, allows S. aureus to 
evade the uptake and killing by host neutrophils. It has been shown previously that CP 
serotype 5 retains more cell-associated CP while type 8 tends to release more CP into the 
supernatant. This research focused on whether this phenomenon is dependent upon the 
serotype-specific capHIJK genes that vary between the two serotypes. 6850, a methicillin-
sensitive S. aureus (MSSA) serotype 8 strain, is a well characterized clinical isolate that 
was used in this study. This strain was subjected to two allelic replacement steps: the first 
step to replace the cap8HIJK genes with an ermB cassette, creating mutant 6850 (CP-); the 
second step to replace the ermB cassette with the cap5HIJK genes, which resulted in the 
creation of mutant 6850 (CP5). All 3 strains were characterized genotypically by PCR and 
phenotypically for growth rate, metabolic profile, and CP production. ELISA inhibition 
studies revealed that serotype 5 and the serotype 8 variants of S. aureus 6850 produced 
similar levels of cell-associated CP. These results suggest that cell wall anchoring of S. 
aureus CP5 and CP8 is not serotype specific, but instead is dependent on the genetic 
background of the bacterial strain. A better understanding of the anchoring mechanism may 
allow for development of alternative immunotherapeutics for S. aureus.  
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INTRODUCTION 
 Staphylococcus aureus, an opportunistic bacterial pathogen, is known to cause a 
multitude of human diseases, ranging from skin and soft tissue infections (SSTI) to life-
threatening infections, such as necrotizing pneumonia and blood stream infections that 
lead to sepsis and death (1). To treat these infections, clinicians have often relied on the 
use of antibiotics (2). However, resistance to antibiotics has been a major issue since its 
emergence in the 1940s (3). S. aureus antibiotic resistance is mediated by a mobile 
genetic element (MGE) called staphylococcal cassette chromosome mec (SCCmec) (4). 
SCCmec contains mecA, a gene encoding penicillin-binding protein 2a (PBP2a), which 
has low binding affinity to b-lactams, thus generating a new classification of the 
antibiotic-resistant bacterium called methicillin resistant Staphylococcus aureus (MRSA) 
(5). The growth of antimicrobial resistance, in S. aureus and other types of infectious 
agents, has been deemed a serious threat to global public health by the World Health 
Organization (6). 
MRSA is a serious threat to the U.S., causing more than 80,000 severe infections 
and 11,000 deaths annually, and is also the leading cause of nosocomial infections (2). 
While MRSA, first detected in 1959 (7), was initially regarded as a hospital associated-
MRSA (HA-MRSA), within the past two decades, community acquired-MRSA (CA-
MRSA) has emerged as a threat outside of the hospital setting (8). In contrast to HA-
MRSA infections, CA-MRSA infections can occur in healthy individuals suggesting that 
CA-MRSA strains have greater virulence than HA-MRSA strains (8, 9). Since treatment 
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options are becoming limited for MRSA, it is imperative that the basis of its pathogenesis 
is understood. Without this knowledge, there will be no innovation for new therapeutics.  
In addition to its antibiotic resistances, MRSA uses a wide variety of virulence 
factors that allow for its pathogenic success, a few major categories being exotoxins, 
enzymes, and cell-wall anchored proteins (10). A few of the major toxins secreted, such 
as Panton-Valentine Leukocidin (PVL), alpha-hemolysin, and phenol-soluble modulins 
(PSMs) are known to cause pore formation in cell membranes, causing destruction of 
erythrocytes and human neutrophils (11–13). Cell-wall associated virulence factors, such 
as staphylococcal protein A (SpA) and capsular polysaccharides, promote immune 
evasion (14). S. aureus capsular serotypes 5 and 8 account for ~25% and ~50% of human 
clinical isolates while ~25% could not be typed (15–18). S. aureus exotoxins and 
enzymes are regulated by a polycistronic locus called accessory gene regulator (agr) (19). 
The transcriptional products of agr, RNAII and RNAIII, are driven by promoters P2 and 
P3, respectively, and function as a positive feedback loop (20, 21). RNAII’s function is to 
control the production of PSMs as well as the quorum-sensing lactone peptide 
autoinducing peptide (AIP), among other things (22). RNAIII controls the production of a 
number of toxins, such as proteases, lipases, alpha-hemolysin, and leukocidins, as well as 
S. aureus capsular polysaccharide (22). RNAIII has also been reported to stabilize the 
mRNA of another global regulator called multiple gene regulator, mgr (23). mgr has been 
shown to affect the synthesis of nuclease, lipase, protease, coagulase, alpha-toxin, protein 
A, and capsular polysaccharides (24). As seen above, S. aureus has a wide repertoire of 
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virulence factors for pathogenic success. This study will focus on is S. aureus capsular 
polysaccharide and its role in S. aureus pathogenesis.  
Capsular Polysaccharides 
 Capsular polysaccharides (CPs) are a component of the cell envelope of S. aureus 
and other invasive pathogens (25). CPs confer resistance to phagocytosis and allows for 
persistence in the bloodstream of the host (26, 27). Nearly all S. aureus strains contain a 
capABCDEFGHIJKLMNOP locus which encodes for enzymes that synthesize CP (25). 
While the regions surrounding capHIJK are nearly identical, capHIJK is the unique 
region that specifies for chemical diversity, which is depicted in Figure 1 (28).  
 
Figure 1. S. aureus cap5 and cap8 Gene Loci. Depicts the homology between Capsular Polysaccharide Serotypes 
5 and 8. Adapted from Sau, et al 1997.  
CPs are composed of repeating tri-saccharide structures comprised of these sugars: D-N-
acetyl mannosaminuronic acid (ManNAcA), L-N-acetyl fucosamine (L-FucNAc), and D-
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N-acetyl fucosamine (D-FucNAc) (29). Serotypes 5 and 8 share identical monosaccharide 
composition and sequence, but differ in glycosidic linkages between the sugars and the 
sites of O-acetylation, as shown in Figure 2 (30–32).  
 
  
Figure 2. S. aureus cap5 and cap8 Structure and Linkages. It shows the different sites of O-acetylation and 
glycosidic linkages between the sugars. Taken from Weidenmaier C. et al, 2015. 
These serotypes are classified as microencapsulated, distinguishing them from the 
extremely rare mucoid serotypes 1 and 2 that produce more CP (33). CP production has 
also been correlated with resistance to in vitro phagocytic uptake and killing (34, 35). 
This feature may be indicative of S. aureus’ ability to persist in the bloodstream of its 
hosts. The virulence patterns of serotypes 5 and 8 have been established in vivo 
previously, reporting that serotype 5 has longer bloodstream persistence than serotype 8 
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when the parent strain, originally serotype 5, was changed to serotype 8 through allelic 
replacement (36). Another trend that has been correlated with serotype is the anchoring of 
CP to the cell wall. It was shown previously that S. aureus strains vary in the amount of 
CP they produce, with CP5 strains shedding little CP into the supernatant and CP8 strains 
shedding much more in the supernatant, in vitro and in vivo (37). The CP anchoring 
mechanism has been linked to a family of homologous proteins called LytR-CpsA-Psr 
(LCP), which is found in many Gram-positive organisms (38, 39). However, it has not 
been determined whether the serotype specific genes of CP5 and CP8 would play a role 
in CP secretion. This study is focused on the strain specificity of CP anchoring and will 
evaluate the behavior of a CP8 strain and how its CP is influenced when it is isogenically 
mutated to CP5. 
 S. aureus strain 6850 (spa type t185; sequence type 50 [ST50]) is a well 
characterized, methicillin-sensitive clinical isolate with a CP8 phenotype (40). It was 
isolated from a patient where it began as a skin abscess and progressed to S. aureus 
bacteremia, osteomyelitis, septic arthritis, and multiple systemic abscesses (40). Strain 
6850 demonstrates phagosomal escape, cytotoxicity, cellular invasiveness, and is 
hemolytic to rabbit and sheep erythrocytes (40–43). 
Specific Aims 
To elucidate the mechanism of S. aureus capsular polysaccharide cell membrane 
anchoring, we will:  
(1): Create a Streptomycin-resistant strain of 6850 
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(2) Induce a cap8HIJK knock out in 6850 strain through phage transduction and 
allelic replacement. 
(3) Through allelic replacement, construct a 6850 strain producing CP5.   
 (4) Compare and evaluate the cell-associated CP in strains 6850 (CP8), 6850 
(CP5), and 6850 (CP-).  
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METHODS 
 
Bacterial Growth Conditions 
Tryptic Soy Broth was used to grow S. aureus strains while Luria Bertani was 
used to grow both E. coli and S. aureus, with and without 1.5% agar. The culture medium 
contained ampicillin (Amp) at 100 µg/mL, chloramphenicol (Cm) at 10 µg/mL, 
erythromycin (Em) at 5 µg/mL, streptomycin (Sm) at 500 µg/mL, as needed. For CP 
measurements, the bacteria were grown in RPMI + 1% casamino acids. 
 
Generation of 6850 Smr Mutant 
 Streptomycin is an aminoglycoside that targets the prokaryotic 30S ribosomal 
protein S12 and inhibits proof-reading of protein synthesis (44). Streptomycin resistance 
is a useful antibiotic marker in isolating the bacteria of interest from the commensal flora 
in animal experiments. In order to generate mutants with Smr, 100 µL of frozen stock 
culture was plated onto Sm agar and incubated at 37°C overnight. Single colonies that 
grow are assumed to have single mutations in the rpsL gene that encodes the ribosomal 
subunit. While this bacterium may have a mutation in the rpsL gene, the strain was 
phenotypically evaluated and appeared to be identical, exhibiting the same growth rate, 
hemolysis on BAP, and the same metabolic profile on API Staph test strips (Biomerieux 
Inc., Durham, NC). 
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Cap8HIJK deletion Mutation 
The deletion of the cap8HIJK region is facilitated by allelic replacement, using 
plasmid pAP1.2 that was constructed previously (36). It carries an erythromycin 
resistance gene, ermB. The ermB region originated from Tn917 and has a length of 1.2 
kB. The ermB gene in pAP1.2 is flanked by genes capFG and capLM that are necessary 
for homologous recombination into the chromosomal cap8 locus. The size of plasmid 
pAP1.2 is 12,284 bp and is comprised of the features listed below. 
 
Temperature-Sensitive Origin of Replication 
 pAP1.2 contains a temperature sensitive origin of replication. The origin of 
replication is the site where DNA polymerases attach and initiate plasmid replication. 
This site is altered at temperatures higher than 30°C, preventing the plasmid replication 
and plasmid transfer to daughter cells in a culture incubated at 42°C. This characteristic is 
essential in selecting for bacteria that have the plasmid integrated into the host 
chromosome. 
 
Antibiotic Resistance 
 Plasmid pAP1.2 contains the cat gene, which encodes for chloramphenicol O-
acetyltransferase conferring chloramphenicol resistance. This gene allows for selection of 
the S. aureus that carry the plasmid on Cm agar.  
 Plasmid pAP1.2 also contains the ermB gene that is flanked by the genes capFG 
and capLM. This gene replaces the serotype-specific cap8HIJK region and is used for 
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selection of bacterial cells that have integrated pAP1.2 into the chromosome at 42°C and 
for cells that have undergone allelic replacement, replacing cap8HIJK with ermB.  
 
Strain Definitions 
 S. aureus strain RN4220 is the typical strain used for plasmid transfer because it 
is restriction negative, allowing it to uptake DNA from Escherichia coli (E. coli). Genetic 
manipulations necessary to create plasmids are much more easily accomplished in E. coli. 
Thus, the plasmids used in this study were first created in E. coli strain DH5a as 
described by Watts et al. (2005) and transferred to S. aureus RN4220. 
 
Genetic Manipulations 
 The cap8HIJK deletion mutant was created by performing transduction to move 
the pAP1.2 plasmid into 6850 Smr, performing allelic replacement, which aids the 
wildtype cap8HIJK region to be replaced by the ermB cassette in pAP1.2 by homologous 
recombination.  
 
Transduction 
Transduction is described as using a phage particle to transfer DNA between 
bacterial strains. After viral DNA has entered the bacterium, it shuts down the bacterial 
metabolic processes and randomly cleaves bacterial DNA with its genetic products. As 
the viral particles replicate, fragments of bacterial chromosomal DNA and whole 
plasmids are packaged into the virus particle at low frequency. Phage transduction is 
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performed by using these virus particles to infect billions of recipient bacterial cells with 
random pieces of donor bacterial DNA. A low number of phage that contain the desired 
DNA fragment or plasmid DNA will then infect the recipient bacterial cell and transfer 
the DNA fragment or plasmid to the recipient. The bacterial cells are then plated on TSA 
with appropriate antibiotics selection, which kills the bacterial cells that did not receive 
the correct DNA, allowing only the correct recipient bacterial cells to grow. 
Phage lysate was created by propagating f80a through the donor strain RN4220 
(pAP1.2) at 30°C.  
6850 Smr was grown overnight in 5 mL of LB with 5 mM CaCl2 at 37°C on a 
rotator. 1 mL of the bacteria were then pelleted and resuspended in 1 mL of fresh LB 
with 5mM CaCl2. 0.5 mL of f80a (pAP1.2) and 0.5 mL of LB with 5mM CaCl2 were 
added to the bacteria, and the mixture was incubated in a 30°C water bath with shaking 
for 30 min. Following incubation, 1 mL of ice cold 20mM sodium citrate was added to 
the mixture, and the sample was centrifuged at 3500 RPM for 10 min. Following 
centrifugation, the supernatant was aspirated and the pellet was resuspended in 1 mL of 
20 mM ice cold sodium citrate. 100µL of this resuspension was plated onto Cm agar with 
20mM sodium citrate. The rest of the resuspension was then centrifuged for 5 min at 
14,000 RPM and the pellet was resuspended in 100 µL of 20 mM sodium citrated and 
plated onto Cm agar with 20mM sodium citrate as well, called the “pellet” plate. The 
plates were then incubated at 30°C for 48 hours. 
Cmr colonies were then struck out on Em agar, Sm agar, TSA, and BAP in order 
to confirm antibiotic susceptibility profile, colony morphology, and hemolytic profile, in 
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order to rule out generation of spontaneous Cmr colonies. The presence of the plasmid 
was then confirmed by plasmid extraction and restriction digest of the donor strain and 
the recipient strain. 
Plasmid DNA was isolated using Qiagen Plasmid Mini Kit. An additional step 
was added to the plasmid extraction protocol. After resuspending the bacterial pellet in 
P1 buffer, 30 µL of 1 mg/mL lysostaphin was added and the resuspensions were 
incubated at 37°C for 1 hour. Lysostaphin is an enzyme that hydrolyzes the penta-glycine 
bridge cross-linking peptidoglycan strands, facilitating S. aureus lysis (45). Following 
isolation, the plasmids were incubated with Invitrogen’s restriction enzymes at 37°C for 1 
hour. The enzymes used for digestion were BamHI and HindIII. The DNA digests were 
then compared via agarose gel electrophoresis.  
 
Allelic Replacement 
Once the presence of the plasmid pAP1.2 has been confirmed in 6850 Smr, allelic 
replacement is necessary in order to complete the mutation. The plasmid contains 
fragments of the locus: capFG and capLM. The region of interest, cap8HIJK, has been 
replaced with the ermB cassette while retaining function for the rest of the locus 
following the mutation. The genes flanking cap8HIJK, capFG and capLM, are necessary 
for homologous recombination by using the homology between the genes. The plasmid is 
encouraged to integrate into the chromosome by growing the plasmid carrying bacteria at 
42°C in the presence of chloramphenicol. With the high temperature, the plasmid cannot 
be replicated. On the rare occurrence of homologous recombination, the chloramphenicol 
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selects for the bacterial cells that contain the integrated plasmid. Upon bacterial division, 
the daughter cells will also carry the plasmid integrated into the chromosome. The 
integration PCR for Product A used the following primers: cap8D polyA-F 
(AGTCCAAGGTAAAATTGCGG) and ermB_R (CTTTGGCGTGTTTCATTGCT). The 
DNA fragment was amplified using the DreamTaq polymerase supplied by ThermoFisher 
Scientific with the following program: 95°C for 3 min; 95°C for 30s; 53°C for 30s; 72°C 
for 4 min and 30 sec; 72°C for 10 min. The integration PCR for Product B used the 
following primers: ermB_F (CGAGTGAAAAAGTACTCAACCAAA) and 10402R1 
(TTTCCCGGGCAATGTGCACCATAAAT). The DNA fragment was amplified using 
the DreamTaq polymerase supplied by ThermoFisher Scientific with the following 
program: 95°C for 3 min; 95°C for 30s; 50°C for 30s; 72°C for 3 min; 72°C for 10 min.  
After integration was confirmed via PCR, the bacteria containing the integrated 
plasmid is shifted to grow at 30°C without antibiotics, initiating plasmid rolling circle 
replication. During this step, plasmid excision occurs and approximately 50% of the 
excisions will occur on the opposite side of the integration, which results in replacing the 
wildtype locus with mutated locus in the chromosome (46). After excision of the plasmid 
from the chromosome, the bacteria are capable of retaining the plasmid. However, 
without antibiotic selection, the plasmid no longer provides essential genes for the 
bacterium, causing it to not be replicated during cell division. Thus, the daughter cells of 
the bacteria will no longer contain the plasmid with subsequent divisions.  
The correct mutants would be Cms and Emr, indicating that the bacteria had lost 
plasmid pAP1.2 but retained the mutated cap8 locus. 
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Genetic Confirmation of the Mutant 
 The genetic analysis of the wildtype and the potential mutants were analyzed with 
crude DNA extracts and performing the following PCR reactions. Crude bacterial DNA 
extracts are made by incubating a bacterial colony in lysis buffer (Tris buffer containing 
Triton X-100, Tween 20, and Proteinase K) at 60°C for 10 min, then 98°C for 10 min.  
 
cap8HIJK Amplification 
 In addition to phenotypic confirmation of the bacteria, genetic analysis of the 
mutated locus is necessary. The locus was amplified by using the capG-F 
(ACAAGGCCTGAAATCATTCG) and capL-R2 (CGGTAAGCTTTAAATGTGTC) 
primers that are supplied by Integrated Data Technologies. The DNA fragment was 
amplified by using the enzyme DreamTaq DNA Polymerase from ThermoFisher 
Scientific and using the following program: 95°C for 3 min; 95°C for 30s; 50°C for 30s; 
72°C for 5 min; 72°C for 10 min.  
 
cat Amplification 
 cat amplification is performed in order to verify that the bacteria no longer carry 
the plasmid. The primers used were catF (GAACTGGTTACAATAGCGACGG) and 
catR (TCCTGCATGATAACCATCACAA). The DNA fragment was amplified by using 
the enzyme Taq DNA Polymerase from ThermoFisher Scientific and the following 
program: 94°C for 3 min, 94°C for 45s, 54°C for 30s, 72°C for 1 min, 72°C for 10 min. 
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The PCR products were then compared and analyzed via agarose gel electrophoresis. The 
product size is estimated to be ~400 bp.  
 
ermB Amplification 
 ermB amplification was performed in order to verify the integrity of the mutation 
after integration and excision of pAP1.2. The primers used were ermB_F 
(CGAGTGAAAAAGTACTCAACCAAA) and ermB_R 
(CTTTGGCGTGTTTCATTGCT). The DNA fragment was amplified by using the 
enzyme Taq DNA Polymerase from ThermoFisher Scientific and the following program: 
94°C for 3 min, 94°C for 45s, 53°C for 30s, 72°C for 45s, 72°C for 10 min. The PCR 
products were then compared and analyzed via agarose gel electrophoresis. The product 
size is estimated to be 621 bp.  
 
Phenotypic Confirmation of the Mutant 
Growth Curve Comparison 
 The wildtype and mutant were inoculated in TSB and grown overnight. The 
overnight cultures are then subcultured (1:200 dilution) into fresh TSB and incubated at 
37°C with shaking. The OD650 was taken every 30 minutes for the first two hours, and 
then every 20 minutes until the culture reached stationary phase.  
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Colony Immunoblot Assay 
 CP8 production was evaluated by using the colony immunoblot assay as 
described previously, to confirm that the appropriate mutation had been made (47). First, 
the strains must be inoculated on a TSA plate and incubated overnight at 37°C. In 
addition to the wildtype strain and the mutant strain, other S. aureus strains producing 
CP8 and CP5 and S. aureus strains not producing any capsule were also added to the 
plate as controls. After the overnight incubation, the colonies were transferred onto a 
nitrocellulose membrane and heat fixed at 60°C for 15 min. Following the fixation, the 
membrane was washed twice with PBS and then incubated at 37°C in a 1 mg/mL trypsin 
solution for an hour. The trypsin enzyme is used to digest surface protein A that 
potentially could cause false positives. After two PBS washes after the trypsin digestion 
step, the filter was blocked with 0.05% skim milk for 1 hr and washed again twice with 
PBS containing 0.05% Tween 20 (PBS-T). CP5 or CP8 specific antibodies were diluted 
in 0.05% PBS-T and incubated with the filter at 37°C for 30 min. After another two 
0.05% PBS-T washes, a secondary antibody was added to the membrane and incubated at 
37°C for 30 min. Following the secondary antibody, the membranes were washed three 
times with 0.05% PBS-T and two times with PBS. 3,3’,5,5’ Tetramethylbenzidine 
substrate, supplied by KPL, was then added onto the membrane for development, and the 
membrane was rinsed with water to quench the development reaction. The color level 
was visually scored on a scale of 0 to 4, with <2 being negative, and >2 being positive. 
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Creation of 6850 Smr CP5 
 In order to create a CP5 producing 6850 Smr, allelic replacement was performed 
using the plasmid pCL10:CP5FM that was previously described (Watts, 2005). This 
plasmid contains the cap5HIJK genes within the plasmid and is flanked by cap5FG and 
cap5LM genes that allow for homologous recombination. The mutant strain 6850 Smr 
Dcap8HIJK was used to perform the second allelic replacement.  
 Similar to the creation 6850 Smr Dcap8HIJK strain, f80a was propagated through 
RN4220 (pCL10:CP5FM) to create a phage lysate. 6850 Smr Dcap8HIJK was then 
transduced with f80a (pCL10:CP5FM). Following transduction, the bacteria were 
verified to be carrying plasmids by plasmid extraction and digestion. The sizes of the 
plasmids were compared via agarose gel electrophoresis. The bacteria antibiotic profile, 
hemolytic profile, and colony morphology were also evaluated.  
Integration of the plasmid was performed by growing strain 6850 Smr Dcap8HIJK 
(pCL10:CP5FM) at 42°C with chloramphenicol to select for plasmid integration into the 
chromosome. After passaging, the bacteria were then plated on Cm agar and grown at 
42°C. The integration was verified via PCR. The integration PCR for Product A used the 
following primers: DK10 (TGATGCTACTGAGTACAAATAGCC) and 10402R1 
(TTTCCCGGGCAATGTGCACCATAAAT). The DNA fragment was amplified using 
DreamTaq polymerase supplied by ThermoFisher Scientific and the following program: 
95°C for 3 min; 95°C for 30s; 50°C for 30s; 72°C for 2 min; 72°C for 10 min. The 
integration PCR for Product B used the following primers: cap8D-polyA-F 
(AGTCCAAGGTAAAATTGCGG) and KK18 
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(ACAAGGATCCTTTTAGTTTATCAGGCG). The DNA fragment was amplified using 
DreamTaq polymerase supplied by ThermoFisher Scientific and the following program: 
95°C for 3 min; 95°C for 30s; 53°C for 30s; 72°C for 4 min; 72°C for 10 min.  
Following verification of integration, the bacteria were then passaged at 30°C for 
excision of the plasmid. The passages underwent dilution plating for single colonies that 
were analyzed for their antibiotic resistance profile, hemolytic profile, and colony 
morphology. In contrast to the 6850 Smr Dcap8HIJK strain, the 6850 Smr CP5 strain will 
have lost its Emr because the ermB cassette will have been replaced by the cap5HIJK 
genes. The allelic replacement was then confirmed with PCR using cap5HIJK specific 
primers and the phenotype was confirmed with colony immunoblot. The cap5HIJK PCR 
used the following primers: cap5HIJK-F(GGTTTGCTGAAAAACCAGTCC) and 
cap5HIJK-R (CGTTGCAAACAATTCACTGG). The DNA fragment was amplified 
using DreamTaq polymerase supplied by ThermoFisher Scientific and the following 
program: 95°C for 3 min; 95°C for 30s; 52°C for 30s; 72°C for 2 min and 30 sec; 72°C 
for 10 min. 
 
Coating of ELISA Plates with Poly-L-Lysine and Purified Capsular Polysaccharide 
 ELISA plates are coated with lysine-coupled CP as previously described (48). 
Due to plastic’s inherent negative charge, ELISA plates are incapable of adsorbing CPs 
because of CPs natural negative charge. However, if CPs are coupled with Poly-L-
Lysine, a positively charged polymer, CPs would be able to adsorb onto plastic as a 
secondary attachment through Poly-L-Lysine.  
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Inhibition Enzyme Linked Immunosorbent Assay  
 The Inhibition ELISA is an assay that is designed to evaluate and quantify the 
amount of CP made by S. aureus.  
 Bacterial strains were grown for 24 hours in RPMI with 1% Casamino acids. The 
bacteria were then spun down at 3500 RPM for 10 min at 4°C. The supernatants were 
then aspirated. The bacterial pellet was washed with 10 mL of Trypsin buffer. The re-
suspension was then spun down again for 10 min at 4°C at 3500 RPM. The pellet was 
incubated with a 1 mg/mL solution of Trypsin at 37°C for 1 hour with end over end 
rotation. After the 1 hr incubation, the bacteria were centrifuged, the supernatant was 
aspirated, and the bacteria were washed with PBS-T and centrifuged again. The bacterial 
pellet was then re-suspended in 0.2mL of PBS-T. The bacteria were then serially diluted 
in a V-well microtiter plate. Serum from a rabbit immunized with CP5-CRM or CP8-
CRM was diluted in PBS-T and added to the microtiter plate. The plate was then mixed 
at 700RPM for 1 min and incubated in 4°C overnight. The CP5/CP8 coated plate was 
washed 3x with PBS-T and then incubated with 0.05% skim milk at 4°C overnight as 
well. 
 Following the overnight incubation, the microtiter plate containing bacterial 
dilutions mixed with diluted CP antiserum was spun at 2000 RPM for 10 min at 4°C. 
During the centrifugation step, the CP5/CP8 coated plate that was incubated with 0.05% 
skim milk was washed 3x with PBS-T. After centrifugation, a total of 200 µL (100µL x 
2) was taken from each well of the microtiter plate and added to the coated ELISA plate 
	19 
and incubated at 25°C for 2 hours. The coated plate was then washed 3x with PBS-T and 
100 µL of alkaline phosphatase-conjugated Protein G/A (Thermo Fisher Scientific), 
diluted 1:5000 in PBS-T, was added to the coated plate and incubated at 25°C for 2 
hours. The plate was then washed 3x with PBS-T and 1x with PBS following incubation. 
A 10 mL solution of 0.05 M carbonate/bicarbonate buffer (pH=9.6), 50µL 1M MgCl2, 
and 1 p-nitrophenyl phosphate tablet (Sigma Aldrich) was made and 100 µL of this 
solution was added to each well of the ELISA plate for development. The plate was then 
monitored for development by reading the absorbance at 405nm. The final reading done 
on the plate was when the sera-only wells reached an OD of ~1.0. 
 The data were then recorded and plotted as the CP Binding Ratio (the average OD 
of the duplicate sample wells/average OD of the antiserum only control) against the 
dilution of bacteria.  
 
api Staph Metabolic Strip Assay 
 The api Staph assay was performed as described in the manufacturer’s protocol. 
In short, the bacteria are grown on a BAP overnight and one colony is resuspended in api 
Staph Medium supplied to achieve a turbidity of one McFarland. The bacterial 
suspension was then added into the wells of the metabolic strip and incubated at 37°C 
overnight. The next day, the color of each compartment was noted and marked as positive 
or negative, as described by the manufacturer’s protocol. The metabolic reactions of the 
parental vs. mutant strains were compared.  
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RESULTS 
Generation of 6850 Smr mutant 
  
Plating of 6850 frozen milk stock on Sm agar in 3 separate trials yielded 8 
colonies. Of the 8 colonies, only a single colony grew similarly to the 6850 wildtype 
strain. This indicated that this colony did not have any growth defects when compared to 
the wildtype strain albeit developing a new mutation in the rpsL gene. The growth curve 
can be found in Figure 3.  
 
Figure 3. Growth Curve Assay of 6850 Smr. This graph shows the growth rate of three different Smr colonies 
over time compared with the wildtype strain. 6850 Smr-#1 grew most similarly to the wildtype strain and used 
as the 6850 Smr mutant. 
To ensure that there were no metabolic changes in the new Smr mutant, an api 
Staph Metabolic strip was used to ensure they had the same metabolic profile. 
Phage transduction of 6850 Smr with phage f80a (pAP1.2) 
 For transduction, 6850 Smr was resuspended in 5 mL of LB broth with an 
OD650=4.5 (OD650=4.3 is ~5x109 CFU/mL). The plaque forming units (PFU) of the f80a 
(pAP1.2) was estimated to be ~ 1x1010 PFU/mL. By combining 1 ml of the bacterial 
suspension and 0.5 ml of the phage preparation, the multiplicity of infection (MOI) was 
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estimated to be ~1. The MOI is described as the ratio of virus particles to the number of 
target cells. Following 48 hours of incubation, the transduction sample plated on Cm agar 
with 0.1 mL of the resuspension had ~300 colonies of bacteria, while the “pellet” plate 
had ~500 colonies with a lawn of colonies in the middle of the plate.  
 A subset of transductant colonies were then evaluated for their antibiotic profile, 
colony morphology, and hemolytic profile at 30°C. The plates with ~300 colonies were 
replica plated across Cm agar and Em agar. Only 12 colonies were both Cmr and Emr 
post replication, indicating that the transduction had low efficiency. These colonies were 
also Smr and had the same hemolytic profile as the wildtype strain. The majority of the 
colonies were Cmr and Ems, which does not fit the antibiotic profile of interest. A sample 
of the antibiotic profiles are shown in Table 1. 
Sample Cm 10 Em 5 Sm 500 TSA BAP 
Colony 1 ++ ++ ++ Yellow ++ 
Colony 2 ++ ++ ++ Yellow ++ 
Colony 3 ++ ++ ++ Yellow ++ 
Colony 4 ++ - ++ Yellow ++ 
Colony 5 ++ ++ ++ Yellow ++ 
6850 Smr - - ++ Yellow ++ 
RN4220 
pAP1.2 
++ ++ - White + 
Table 1. Antibiotic Resistance Profiles of 6850 Smr pAP1.2 Transductants. The strains’ growth is rated as ++ 
(normal growth), +/- (slightly inhibited growth), and – (no growth). The TSA plate notes the colony 
pigmentation. The BAP symbols indicate level of hemolysis, ++ as complete hemolysis, + as slight hemolysis, and 
– as no hemolysis. 
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The correct transductants will display the antibiotic profiles that resemble both the donor 
strain and the recipient strain. Colony 4 exhibited the incorrect antibiotic profile and was 
not chosen for plasmid integration passaging.  
Plasmid extraction and HindIII digests were performed on the colonies that were 
both Cmr and Emr. The plasmid digestions are shown in Figure 4. The digestion verified 
that the plasmid was correct: the bands produced by the digestion had the three expected 
sizes, 8.8 kB, 2.3 kB, and 1.2 kB. The Cmr/Ems bacteria plasmid profiles were also 
examined. The plasmid profiles differed in that these bacteria were missing the 2.3 kB 
band that contains the ermB cassette (not shown), thus explaining their erythromycin 
sensitivity. 
 
Figure 4. HindIII Digest of Plasmid pAP1.2. (1): Log 2 DNA Ladder by NEB. (2): RN4220 (pAP1.2). (3): 6850 
Smr (pAP1.2) #1. (4): 6850 Smr (pAP1.2) #2. 
 
Passaging of 6850 Smr (pAP1.2) and PCR Verification of Integration 
 After the first 24 hour passage at 42°C, the bacteria were plated on Em agar, 
generating 17 colonies at 10-5 dilution and ~100 colonies at 10-4 dilution. Colonies were 
patch plated across Cm agar, Em agar, Sm agar, TSA and BAP, showing all antibiotic 
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resistances, correct morphology, and correct hemolytic profile. Three of these colonies 
were chosen for evaluation by PCR for integration. The schematic of the integration of 
the plasmid is shown in Figure 5  
 
Figure 5. Integration Schematic of pAP1.2 into 6850 Smr. This figure depicts the wild type cap8 locus along with 
the two possible sites of integration of plasmid pAP1.2 into the chromosome of 6850 Smr in the cap8 locus. The 
two theorized PCR products to verify the integration of the plasmid are shown above the potential Integrants. 
The Excisant depicts the mutant after the plasmid is excised correctly from the chromosome.  
 
The PCR revealed that two of the colonies had plasmid integration of the plasmid at 
cap8F and one of the colonies had plasmid integration at cap8L, which can be found in 
Figures 6 and 7, respectively.  
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Figure 6. 6850 Smr pAP1.2 Integration PCR Product A. 1: Log-2 DNA Ladder (NEB). 2: 6850 Smr pAP1.2 
Colony #1. 3: 6850 Smr pAP1.2 Colony #2. 4: 6850 Smr pAP1.2 Colony #3.  
 
Figure 7. 6850 Smr pAP1.2 Integration PCR Product B. 1: Log-2 DNA Ladder (NEB). 2: 6850 Smr pAP1.2 
Colony #1. 3: 6850 Smr pAP1.2 Colony #2. 4: 6850 Smr pAP1.2 Colony #3. 
 
The PCRs differ in that the primers used are at different sites of the cap8 locus. 
When the plasmid integrates at cap8F, the PCR product generated, called Product A, 
spans cap8DEFG to the ermB cassette that replaces the cap8HIJK genes, with an 
estimated product of 5,548 base pairs (bp). The other possible PCR product generated, 
called Product B, begins at the front of the ermB cassette and includes cap8LMN, with a 
product estimated to be 2,950 bp. Theoretically, the pAP1.2 integration PCR should only 
have one of the two integration products detectable by PCR, and in fact, a single 
amplicon dominated in each of the three mutants. However, a low frequency of plasmid 
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excision might have occurred, resulting in a secondary faint band also visible for each of 
the three mutants (Figures 6 and 7). 
  
Passaging of 6850 Smr integrants for excision and PCR verification 
 Passaging the colonies at 30°C in the absence of antibiotic selection results in 
plasmid pAP1.2 excision from the chromosome. During excision, the plasmid can 
undergo homologous recombination on either side of the ermB cassette, thus producing 
the desired Dcap8 mutant, or reconstituting the wildtype genotype. The bacteria were 
blindly passaged three times in TSB over 72 hours, and then were dilution plated at 37°C 
following the fourth passage.  
 The colonies were then patch plated across Cm agar, Em agar, Sm agar, TSA and 
BAP and a number of the antibiotic profiles are shown in Table 2.  
 
Sample Cm 10 Em 5 Sm 500 TSA BAP 
Colony 1 - ++ ++ Yellow ++ 
Colony 2 - ++ ++ Yellow ++ 
Colony 3 - - ++ Yellow ++ 
Colony 4 - ++ ++ Yellow ++ 
Colony 5 - ++ ++ Yellow ++ 
6850 Smr - - ++ Yellow ++ 
RN4220 
pAP1.2 
++ ++ - White + 
 
Table 2. Antibiotic Resistance Profiles of 6850 Smr pAP1.2 Excisants. The strains’ growth is rated as ++ (normal 
growth), +/- (slightly inhibited growth), and – (no growth). The TSA plate notes the colony pigmentation. The 
BAP symbols indicate level of hemolysis, ++ as complete hemolysis, + as slight hemolysis, and – as no hemolysis.  
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Colony 3 exhibited no Emr, thus indicating that the plasmid excision did not retain the 
desired mutation and is called the “Revertant”.  The remaining colonies showed the 
desired phenotype. 
Phenotypic and Genotypic verification of 6850 Smr Dcap8HIJK 
 Colony immunoblot for CP8 was performed on colonies were chosen for 
phenotypic evaluation. A number of colonies chosen for colony immunoblot exhibited 
slight Cmr, but were still included for CP8 expression. Approximately 20 out of the 40 
strains tested gave a score of 0-1 on the CP8 immunoblot (negative reaction), while the 
rest had a score of 2-4 (positive reaction). If the colonies exhibited any Cmr and had 
slight amplification of the cat gene in the cat PCR, which indicates that the plasmid 
pAP1.2 is still present in the bacteria, the colony can continue to be passaged at 30°C 
until the plasmid is no longer present. 
Five colonies were chosen for genetic verification of the mutant, which was 
performed by PCR using primers that annealed at cap8G and cap8L. The parent strain 
should yield a size of 6054 bp amplicon, while the mutant, which had its cap8HIJK 
region replaced with ermB, should yield a 3282 bp amplicon. The PCR product revealed 
that there was a size difference between the wildtype and the knock out colonies as 
shown in Figure 8.  
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Figure 8. PCR Verification of Cap8HIJK Deletion Mutants. 1: Log-2 DNA Ladder (NEB). 2: 6850 Smr. 3: 6850 
Smr Dcap8HIJK Colony #1. 4: 6850 Smr Dcap8HIJK Colony #2. 5: 6850 Smr Dcap8HIJK Colony #3. 6: 6850 Smr 
Dcap8HIJK Colony #4. 7: 6850 Smr Dcap8HIJK Colony #5. 
The colonies were also verified for quality of the ermB cassette with ermB 
specific primers and checked for loss of plasmid with a cat gene specific PCR as shown 
in Figures 9 and 10, respectively. The ermB amplicon is expected to be 621 bp, while the 
cat amplicon is expected to be ~400 bp.  
 
Figure 9. ermB gene PCR for 6850 Smr Dcap8HIJK mutants. 1: Log-2 DNA Ladder (NEB). 2: RN4220 pAP1.2 
(positive control). 3: 6850 Smr Dcap8HIJK Colony #1. 4: 6850 Smr Dcap8HIJK Colony #2. 5: 6850 Smr 
Dcap8HIJK Colony #3. 
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Figure 10. cat gene PCR for 6850 Smr Dcap8HIJK mutants. 1: Log-2 DNA Ladder (NEB). 2: RN4220 pAP1.2 
(positive control). 3: 6850 Smr Dcap8HIJK Colony #1. 4: 6850 Smr Dcap8HIJK Colony #2. 5: 6850 Smr 
Dcap8HIJK Colony #3. 6: 6850 Smr Dcap8HIJK Colony #4. 7: 6850 Smr Dcap8HIJK Colony #5. 
Phage Transduction of 6850 Smr Dcap8HIJK with phage f80a (pCL10:CP5FM) and 
Passaging 
 Transduction of 6850 Smr Dcap8HIJK with phage f80a (pCL10:CP5FM) yielded 
31 colonies in the 0.1 mL plating and a lawn of bacteria on the pellet plate. The MOI was 
estimated to be ~3.56. Of the 31 colonies, 14 colonies were re-streaked at 30°C across 
Cm agar, Em agar, Sm agar, TSA and BAP. The results can be found in Table 2.  
Sample Cm 10 Em 5 Sm 500 TSA BAP 
1 ++ ++ ++ Yellow ++ 
2 ++ ++ ++ Yellow ++ 
3 ++ ++ ++ Yellow ++ 
4 ++ ++ ++ Yellow ++ 
5 ++ ++ ++ Yellow ++ 
6850 Smr 
Dcap8HIJK 
- ++ ++ Yellow ++ 
RN4220 
pCL10:CP5FM 
++ - - White + 
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Table 3. Antibiotic Resistant Profiles of 6850 Smr pCL10:CP5FM Transductants. The strains’ growth is rated as 
++ (normal growth), +/- (slightly inhibited growth), and – (no growth). The TSA plate notes the colony 
morphology. The BAP symbols indicate level of hemolysis, ++ as complete hemolysis, + as slight hemolysis, and – 
as no hemolysis. 
Colonies #1 and #2 were selected for 42°C passaging and were also evaluated for 
plasmid integrity via plasmid extraction and digestion. The results from the BamHI 
digestion and HindIII digestion can be found in Figures 11 and 12, respectively.  
 
Figure 11. BamHI Digestion of Plasmid pCL10:CP5FM. 1: Log-2 DNA Ladder (NEB). 2: RN4220 
pCL10:CP5FM. 3: 6850 Smr Dcap8HIJK pCL10:CP5FM Colony #1. 4: 6850 Smr Dcap8HIJK pCL10:CP5FM 
Colony #2.  
 
Figure 12. HindIII Digestion of Plasmid pCL10:CP5FM. 1: Log-2 DNA Ladder (NEB). 2: RN4220 pAP1.2. 3: 
6850 Smr Dcap8HIJK pCL10:CP5FM Colony #1. 4: 6850 Smr Dcap8HIJK pCL10:CP5FM Colony #2. 
 After passaging the bacteria at 42°C for 24 hrs, the bacterial cultures were dilution 
plated from the 10-4 to the 10-6 dilutions onto Cm agar. Colony #1 generated 4 colonies at 
the 10-4 dilution and Colony #2 generated 44 colonies and one colony at the 10-4 and 10-5 
dilutions, respectively. The number of colonies generated from dilution plating to Cm 
agar after 48 hours of passaging at 42°C can be found in Table 4. 
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48 Hours 
Passaging 
10-4 10-5 10-6 
6850 Smr 
Dcap8HIJK 
pCL10:CP5FM #1 
~500 ~150 12 
6850 Smr 
Dcap8HIJK 
pCL10:CP5FM #2 
~500 ~250 ~60 
Table 4. 6850 Smr pCL10:CP5FM Integration Colony Count for Dilution Plating of 42°C Passaging After Two 
Days. Two different colonies were chosen for passaging at 42°C, forcing integration of the plasmid into the 
chromosome.  
Between the 24 and 48 hours, it can be seen that there was an increase of bacterial 
colonies in the dilution plating, indicating that with longer temperature and antibiotic 
selection, the higher amount of plasmid integration will occur.  
PCR Verification of pCL10:CP5FM Insertion into the Chromosome 
 The schematic of the integration of pCL10:CP5FM into the chromosome can be 
found in Figure 13.  
 
Figure 13. Integration Schematic of pCL10:CP5FM into 6850 Smr Dcap8HIJK. This figure depicts the 6850 Smr 
Dcap8HIJK mutant locus and the two possible sites of integration of plasmid pCL10:CP5FM. The two theorized 
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PCR products used to confirm the integration of the plasmid are also shown above. The Excisant shows the 
resultant locus containing cap5FGHIJKLM after plasmid pCL10 has been excised. 
For Product A and B, the plasmid is expected to integrate at cap8FG and cap8LM, 
respectively. The primers used for Product A would generate an amplicon of 5,109 bp, 
while the primers used for Product B would create an amplicon of 2,389 bp. Eight 
colonies were chosen to be evaluated for integration by PCR. Of the eight colonies 
evaluated, only one colony had the plasmid integrate for Product A, while the other seven 
colonies generated an amplicon for Product B. The PCR data can be found in Figures 14 
and 15. 
 
Figure 14. 6850 Smr Dcap8HIJK pCL10:CP5FM Integration PCR Product A. 1: Log-2 DNA Ladder (NEB).      
2: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #1 3: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #2.      
4: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #3. 5: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #4.     
6: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #5. 7: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #6.     
8: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #7. 6850 9: Smr Dcap8HIJK pCL10:CP5FM Integrant #8. 
 
 
	32 
Figure 15. 6850 Smr Dcap8HIJK pCL10:CP5FM Integration PCR Product B. 1: Log-2 DNA Ladder (NEB).      
2: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #1 3: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #2.      
4: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #3. 5: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #4.     
6: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #5. 7: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #6.     
8: 6850 Smr Dcap8HIJK pCL10:CP5FM Integrant #7. 6850 9: Smr Dcap8HIJK pCL10:CP5FM Integrant #8. 
 
Passaging for excision of pCL10:CP5FM and Patch Plating of Excisants 
 Three colonies were chosen after integration verification for excision. These three 
colonies were passaged four times in 96 hours. The colony count for the dilution plating 
is shown in Table 5. 
Passage #4 10-7 10-8 10-9 
Colony 1 464 42 17 
Colony 2 ~600 61 6 
Colony 3 ~500 51 4 
Table 5. 6850 Smr pCL10:CP5FM Excision Colony Count for Dilution Plating of 30°C Passaging.  
 81 colonies from the three different passages were chosen for patch plating across 
Cm agar, Em agar, Sm agar, TSA, and BAP. At this point, the correct mutants will have 
lost both Cmr and Emr, but retain Smr. At this point, 14 out of the 81 colonies patch 
plated exhibited the correct antibiotic profile, and five of them are shown in Table 3.  
Sample Cm 10 Em 5 Sm 500 TSA BAP 
1 - - ++ Yellow ++ 
2 - - ++ Yellow ++ 
3 - - ++ Yellow ++ 
4 - - ++ Yellow ++ 
5 - ++ ++ Yellow ++ 
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6850 Smr 
Dcap8HIJK 
- ++ ++ Yellow ++ 
RN4220 
pCL10:CP5FM 
++ ++ - White + 
Table 6. Antibiotic Profiles 6850 Smr pCL10:CP5FM Excisants. The strains’ growth is rated as ++ (normal 
growth), +/- (slightly inhibited growth), and – (no growth). The TSA plate notes the colony morphology. The 
BAP symbols indicate level of hemolysis, ++ as complete hemolysis, + as slight hemolysis, and – as no hemolysis. 
Samples 1-4 show the correct antibiotic profile, indicating that the homologous 
recombination had correctly replaced the ermB cassette with the cap5HIJK genes. Strain 
5, however, shows that the excision did not occur on the correct side and the cap5HIJK 
genes were not retained after homologous recombination.  
Colony Immunoblot of 6850 Smr with CP5 and CP8 Antibody 
 The fourteen colonies that exhibited the correct antibiotic profiles were evaluated 
by colony immunoblot for both CP8 and CP5 production. The 14 colonies were all given 
a 0 score for color in the CP8 colony immunoblot and were given a score of 4 in the CP5 
immunoblot, indicating that the ermB gene had been replaced with functionally active 
cap5HIJK genes in these strains. 
cat PCR and Cap5HIJK PCR confirmation 
 cat PCR was performed to ensure that the bacteria no longer carried the 
pCL10:CP5FM plasmid, the PCR data indicated that no amplicons were detected in the 
strain 6850 (CP5) mutants (Figure 16). 
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Figure 16. cat gene PCR for 6850 Smr (CP5). 1: Log-2 DNA Ladder (NEB). 2: RN4220 pCL10:CP5FM. 3: 6850 
Smr (CP5) Colony #1. 4: 6850 Smr (CP5) Colony #2. 5: 6850 Smr (CP5) Colony #3. 6: 6850 Smr (CP5) Colony #4. 
 A cap5 PCR was also performed on these strains, generating a faint 4 kB product. 
This PCR is specific to cap5HIJK because there is very little homology between the CP5 
and CP8 sequence. The PCR data for this can be found in Figure 17. 
 
Figure 17. 6850 Smr Cap5HIJK PCR. 1: Log-2 DNA Ladder (NEB). 2: Newman Smr. 3: 6850 Smr (CP5) Colony 
#1. 4: 6850 Smr (CP5) Colony #2. 5: 6850 Smr (CP5) Colony #3. 6: 6850 Smr (CP5) Colony #4. 7: 6850 Smr (CP8). 
Growth Curve and api Staph Assay 
 A growth curve and API staph assay was performed on CP5 mutants to ensure 
that there was neither growth defects nor metabolic alterations due to the 42°C passaging. 
The growth curve data can be found in Figure 18. The API assay results were identical 
for the WT and CP5 mutant strains. 
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Figure 18. Growth Curve Data for 6850 Smr (CP5) Mutants.  
 
ELISA Inhibition Comparing 6850 Smr (CP8), 6850 Smr Dcap8HIJK, and 6850 Smr 
(CP5) 
 The ELISA Inhibition is a quantitative method of analyzing the amount of 
bacterial cell-associated CP that can bind and adsorb capsular antibodies in diluted rabbit 
antiserum. A comparison was done among 6850 Smr (CP8), 6850 Dcap8HIJK, 6850 Smr 
(CP5), and 6850 Smr Revertant, as shown in Figure 19.  
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Figure 19. ELISA Inhibition of 6850 Smr, 6850 Smr Dcap8HIJK, 6850 Smr (CP8) Revertant, and 6850 Smr (CP5). 
The ELISA Index is used to standardize the level of development between different strains. The ELISA Index is 
plotted against the dilution of bacteria. CP5-CRM Bleed #5: rabbit serum used to detect CP5. CP8-CRM Bleed 
#9: rabbit serum used to detect CP8. 
The level of inhibition that each of the bacterial strains exhibits is examined at the 
50% binding level (ELISA index = 0.5) and compared to the culture dilution level of the 
bacterial suspension used to absorb CP antibodies. As expected, 6850 Smr (CP-) showed 
no inhibition in the assay, displaying a 50% binding level greater than one, which is 
consistent with its CP- phenotype. In comparing the capsule producing strains, it can be 
seen that 6850 Smr (CP8) and 6850 Smr (CP5) express CP on roughly the same level, 
exhibiting a 50% binding level at 1:3.28 and 1:4.31 culture dilutions, respectively. Strain 
6850 Smr (CP8) Revertant underwent the same genetic manipulations as the 6850 Smr 
Dcap8HIJK mutants, but when homologous recombination occurred, it retained its 
wildtype locus. The Revertant was kept as a control to show that passaging at 42°C had 
no deleterious effects on the metabolism, growth rate, or CP production levels. The 
Revertant appeared to produce slightly more CP than the parental strain, a 50% binding 
level of 1:6.28, but further studies would need to be performed to verify the 
reproducibility of this finding.  
It should be noted that different antibodies are used to detect the CP5 and CP8 
strains, which are shown above in Figure 19. Although the immunization regimens for 
these rabbits were identical, such as the amount of CP used for immunization, date of 
injection, and frequency of immunization, the titer of the antibodies to CP5 and CP8 still 
differed. This difference is manifested in the different level of dilutions used in the assay, 
1:2,000 for CP5 and 1:5,000 for CP8. Unfortunately, sera have not been identified in our 
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laboratory that can react equally for CP5 and CP8 and have the same titer. Moreover, 
chemical assays to measure the polysaccharides also cross react with other 
glycopolymers, like wall teichoic acid, on the bacterial surface. 
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DISCUSSION  
 S. aureus is a dangerous human pathogen that is known to cause numerous human 
diseases and is the leading cause of nosocomial infections in the US (2). CPs have been 
shown to play a role in evasion of the host immune system, specifically host neutrophils 
(14). It was shown previously that CP5 strains retained CP on their surface, while CP8 
strains would shed their CP, which could be detected in culture supernatants or in the 
plasma of infected mice (37). The similar study of this thesis was performed previously, 
where a native CP5 strain, Reynolds, was converted into a CP8 strain to see if the 
biologic activity of CPs were comparable (36). It was shown that both the parent 
Reynolds (CP5) strain and the Reynolds (CP8) strain produced cell-associated CP and 
shed little into the supernatant (37). This thesis was focused on setting the groundwork to 
examine whether a native CP8 strain, when mutated to produce CP5, would retain its 
phenotypic characteristics and shed CP5 into the supernatant. In creating 6850 (CP5), a 
comparison can now be drawn between the two strains in future studies outside the scope 
of this project.  
 There are a few limitations of this project. The experiments performed in this 
project, such as the ELISA inhibition, need repetition in order to determine whether some 
of the differences observed reach statistical significance. In addition, a purified CP 
standard curve should be added in the ELISA inhibition. It will allow for better 
quantification of CP, down to ng/mL. Lastly, the ELISA inhibition should be plotted 
against CFU/mL instead of cultural dilution. This will allow for a more accurate 
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comparison between numbers of bacteria, which gives more specific determination of CP 
production.  
 CP is currently being studied as a vaccine target, as both CP5- and CP8 specific 
antibodies mediate CP type-specific opsonophagocytic killing in vitro, which is only 
effective if they are agar-grown, where strains retain their cell-associated CP (25, 29, 35, 
37). However, if both CP5 and CP8 strains are broth-grown, only CP5 antibodies 
displayed opsonic properties, indicating that shedding CP8 could interfere with capsular 
antibody-mediated opsonophagocytic killing. Passively immunized mice were also 
protected against bacteremia provoked by CP5 strains, but were not protected against 
CP8 strains, indicating the potential interference soluble CP causes by preventing opsonic 
antibody binding to the encapsulated bacterial surface (29, 37, 49). The future studies 
involving the strains created in this thesis, 6850 Smr (CP8) and 6850 Smr (CP5), would 
have implications on future vaccine development, potentially focusing vaccine 
development on S. aureus strains that retain CP on the cell wall rather than the CP 
shedding strains. In an era when the number of effective antibiotics are limited, basic 
research is needed on therapeutics that target the human immune system to act in concert 
with antibiotic therapy.  
CONCLUSION 
 The goal of this study was to create isogenic mutants of S. aureus that differed 
only in the production of capsular polysaccharide. The parental strain 6850 produces 
CP8, which is cell associated but also shed into the culture medium during growth. Using 
methods of transduction and allelic replacement, we created an isogenic acapsular mutant 
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of 6850 (CP8) that lacked cap8HIJK and was called 6850 (CP-). This acapsular mutant 
was subjected to another round of transduction and allelic replacement to introduce 
cap5HIJK into the chromosome, yielding a CP5 producing mutant called 6850 (CP5). 
The results of ELISA inhibition assays revealed that 6850 (CP8) and 6850 (CP5) 
produced similar levels of CP, whereas 6850 (CP-) produced no CP. The growth rate and 
metabolic profile of all three strains were identical. These isogenic strains can now be 
used in future studies by the lab to assess CP5 and CP8 shedding in vitro and in vivo in a 
strain with a CP8 genetic background. Moreover, these S. aureus isolates will be useful in 
assessing vaccine efficacy against strains potentially capable of shedding either CP5 or 
CP8. 
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